ImmuPharma meets primary goal in additional Lupuzor study

ImmuPharma has met the primary endpoint in additional study, testing Lupuzor, after requests from Investigators and patients involved in the Pivotal Phase III study, permitting patients who participated in the Phase III study, to receive Lupuzor.

The primary endpoint was successfully met, confirming the outstanding and robust safety profile of Lupuzor™ whilst also reporting no serious adverse events.

Rober Zimmer, Chief Scientific Officer said: “With the positive outcome of this open label extension study with Lupuzor™ having met its primary endpoint and confirming the robust safety profile of the drug, we continue in our discussions with our regulatory experts and potential partners with the key focus of moving Lupuzor™ forward.”

Tim McCarthy, Chairman added: “”We are delighted that Lupuzor™ has again confirmed its robust safety profile and we are confident that Lupuzor™ has the potential to bring a much needed treatment to Lupus sufferers around the world. We look forward to providing our shareholders with further updates as and when appropriate.”